{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:47:46Z","timestamp":1778888866114,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.nuclcard.2024.102077","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T19:28:49Z","timestamp":1734463729000},"page":"102077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["What do changes in myocardial bone-avid radiotracer uptake mean in transthyretin cardiac amyloidosis?"],"prefix":"10.1016","volume":"42","author":[{"given":"Olivier F.","family":"Clerc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.M.","family":"Cuddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nuclcard.2024.102077_bib1","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.nuclcard.2024.102077_bib2","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.221082","article-title":"99mTc bone-avid tracer cardiac scintigraphy: role in noninvasive diagnosis of transthyretin cardiac amyloidosis","volume":"306","author":"Khor","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.nuclcard.2024.102077_bib3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization","volume":"27","author":"Dorbala","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2024.102077_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac 99mTc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2024.102077_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102056","article-title":"SPECT\/CT quantification of 99m-TC PYP uptake to assess tafamidis treatment response in ATTR cardiac amyloidosis","author":"Godoy-Rivas","year":"2024","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2024.102077_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","volume":"24","author":"Rettl","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2024.102077_bib7","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcmg.2022.12.016","article-title":"Tafamidis treatment decreases 99mTc-pyrophosphate uptake in patients with hereditary Ala97Ser transthyretin amyloid cardiomyopathy","volume":"16","author":"Yu","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2024.102077_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102019","article-title":"Quantitative 99mTc-pyrophosphate myocardial uptake: changes on transthyretin stabilization therapy","author":"Vijayakumar","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2024.102077_bib9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2024.102077_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2024.102077_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/13506129.2021.1991302","article-title":"The role of serial 99m Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis","volume":"29","author":"Ross","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.nuclcard.2024.102077_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.carpath.2016.07.001","article-title":"Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis","volume":"25","author":"Stats","year":"2016","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.nuclcard.2024.102077_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijcard.2022.01.036","article-title":"Cardiac microcalcifications in transthyretin (ATTR) amyloidosis","volume":"352","author":"Thelander","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.nuclcard.2024.102077_bib14","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1039\/D4BM00816B","article-title":"Molecular basis for non-invasive diagnostics of cardiac amyloids using bone tracers","volume":"12","author":"Lewkowicz","year":"2024","journal-title":"Biomater Sci"},{"key":"10.1016\/j.nuclcard.2024.102077_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","article-title":"(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis","volume":"121","author":"Pilebro","year":"2016","journal-title":"Ups J Med Sci"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358124007797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358124007797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T19:58:19Z","timestamp":1734465499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358124007797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":15,"alternative-id":["S1071358124007797"],"URL":"https:\/\/doi.org\/10.1016\/j.nuclcard.2024.102077","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What do changes in myocardial bone-avid radiotracer uptake mean in transthyretin cardiac amyloidosis?","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nuclcard.2024.102077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nuclcard.2024.102056","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of American Society of Nuclear Cardiology.","name":"copyright","label":"Copyright"}],"article-number":"102077"}}